Newsroom

Sorted by: Latest

-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Nasdaq Cybersecurity UCITS ETF 13.02.2026 NQCYBREN IE00BF16M727 26,546,927.00 USD 1,081,781,912.26 40.750  ...
-

NATIXIS UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.   (c) Name o...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust NYSE Arca Biotechnology UCITS ETF 13.02.2026 FBTU.LN IE00BL0L0H60 500,002.00 USD 12,745,694.71 25.491  ...
-

NATIXIS UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.   (c) Name o...
-

Worldwide Clinical Trials Completes Acquisition of Catalyst Clinical Research

RESEARCH TRIANGLE PARK, N.C. & NOTTINGHAM, England--(BUSINESS WIRE)--Worldwide Clinical Trials (“Worldwide” or the “Company”), a global contract research organization (CRO), has completed its acquisition of Catalyst Clinical Research, LCC (“Catalyst”) – a specialized oncology CRO and scalable functional service provider (FSP). This strategic transaction creates a combined organization with highly complementary strengths in oncology, biometrics, and FSP capabilities, substantially enhancing Worl...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Capital Strength UCITS ETF 13.02.2026 FTCS. IE00BL0L0D23 275,002.00 USD 9,331,917.51 33.934  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Value Line Dividend Index UCITS ETF 13.02.2026 FVD. IE00BKVKW020 250,002.00 USD 7,540,689.40 30.163  ...
-

Caliber Releases Inaugural Stakeholder Intelligence Report

COPENHAGEN, Denmark--(BUSINESS WIRE)--Caliber, a stakeholder intelligence platform helping organizations build and protect trust, released its inaugural Stakeholder Intelligence Report, revealing global trends in brand, reputation, and data-driven communications. As economic anxiety, AI disruption, and geopolitical uncertainty intensify, leaders across industries are making higher-stakes decisions under conditions of compressed trust and heightened reputational risk. This report equips executiv...
-

Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced that tomorrow it will report new clinical data from two ongoing Phase 3 trials evaluating COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD). The company will be disclosing new clinical data from Part A and Part B from COMP005 and Part A from COMP006. The results are sc...
-

Luna Innovations Incorporated - Notice of Pendency and Proposed Settlement of Stockholder Derivative Action

ROANOKE, Va.--(BUSINESS WIRE)--Luna Innovations Incorporated (OTCMKTS: LUNA), a global leader in advanced fiber-optic technology, today announced a Notice of Pendency and Proposed Settlement of Stockholder Derivative Action....